Conditional approval of oncology medicines in Europe (2017–2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access
- 1Clinical Pharmacology Department, La Paz University Hospital, IdiPAZ
- 2Department of Pharmacology and Therapeutics, School of Medicine, Universidad Autónoma de Madrid
Abstract
Background: Conditional marketing authorisation (CMA) is a European regulatory pathway that enables earlier access to medicines for serious conditions while allowing additional evidence generation after approval. Important questions remain regarding the maturity of supporting evidence, subsequent regulatory outcomes, clinical benefit, and patient access. We characterised the evidentiary basis, regulatory outcomes, clinical benefit, clinical practice guideline incorporation, and downstream access of oncology medicines granted CMA between 2017 and 2022.
Methods: We analysed all antineoplastic medicines granted CMA by the European Commission between 1 January 2017 and 31 December 2022. European Medicines Agency documentation was reviewed to assess regulatory characteristics, post-authorisation obligations, pivotal studies, and outcomes through 31 March 2025. Clinical benefit was evaluated using ESMO–MCBS, while reimbursement was assessed in Spain as an illustrative case of downstream access as of 15 December 2025. Kaplan-Meier analysis estimated time to regulatory resolution and reimbursement.
Results: Twenty-six antineoplastic medicines received CMA, representing 55.3% of all CMA approvals. Most pivotal studies were single-arm (92.9%), open-label, and used surrogate primary endpoints, with a median efficacy sample size of 100.5 participants (IQR 78.5–128.0). Thirty-five specific obligations were imposed, with a median time of 3.95 years (IQR 1.73–5.23) from CMA approval to the latest due date. By 31 March 2025, 53.8% remained under CMA, 38.5% converted to standard marketing authorisation, and 7.7% were withdrawn. Median time to regulatory resolution was 4.46 years. Only 16.7% (3/18) demonstrated substantial clinical benefit according to ESMO–MCBS. Most medicines were subsequently incorporated into ESMO or EHA clinical practice guidelines, although only five (19.2%) received an IA recommendation corresponding to their first CMA-approved indication; two additional medicines received IA recommendations in earlier treatment settings. Public reimbursement was granted for 84.6% (22/26), with a median time of 2.38 years.
Conclusion: Oncology medicines granted CMA were frequently supported by limited and immature evidence, while substantial clinical benefit was uncommon and regulatory resolution often required several years. Future optimisation should combine timely access with timely post-authorisation evidence generation, including comparative clinical and real-world evidence.
Related
- From preclinical promise to regulatory reality: translation of small rodent acute injury therapies to human approval and safety outcomes: A systematic review
- LncACTdb 4.0: an updated resource of experimentally supported ceRNA interactions and multi-level regulatory networks for precision oncology
- The therapeutic landscape of cannabidiol: a systematic review of molecular mechanisms, clinical efficacy in oncology and neurology, and regulatory changes.
- Drug repurposing and treatment optimisation in oncology: regulatory challenges and policy priorities
- Academic treatment optimization studies in oncology and internal medicine: a risk- and burden-adapted regulatory framework for the European Union.
BibTeX
@article{urrozelizalde2026conditional,
title = {{Conditional approval of oncology medicines in Europe (2017–2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access}},
author = {Mikel Urroz-Elizalde and Paloma Moraga-Alapont and María Jiménez-González and Alberto M. Borobia and Antonio J. Carcas-Sansuán},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1959449},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1959449/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Conditional approval of oncology medicines in Europe (2017–2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access
AU - Mikel Urroz-Elizalde
AU - Paloma Moraga-Alapont
AU - María Jiménez-González
AU - Alberto M. Borobia
AU - Antonio J. Carcas-Sansuán
PY - 2026
DA - 2026/10/13
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1959449
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1959449/full
AB - Background: Conditional marketing authorisation (CMA) is a European regulatory pathway that enables earlier access to medicines for serious conditions while allowing additional evidence generation after approval. Important questions remain regarding the maturity of supporting evidence, subsequent regulatory outcomes, clinical benefit, and patient access. We characterised the evidentiary basis, regulatory outcomes, clinical benefit, clinical practice guideline incorporation, and downstream access of oncology medicines granted CMA between 2017 and 2022. Methods: We analysed all antineoplastic medicines granted CMA by the European Commission between 1 January 2017 and 31 December 2022. European Medicines Agency documentation was reviewed to assess regulatory characteristics, post-authorisation obligations, pivotal studies, and outcomes through 31 March 2025. Clinical benefit was evaluated using ESMO–MCBS, while reimbursement was assessed in Spain as an illustrative case of downstream access as of 15 December 2025. Kaplan-Meier analysis estimated time to regulatory resolution and reimbursement. Results: Twenty-six antineoplastic medicines received CMA, representing 55.3% of all CMA approvals. Most pivotal studies were single-arm (92.9%), open-label, and used surrogate primary endpoints, with a median efficacy sample size of 100.5 participants (IQR 78.5–128.0). Thirty-five specific obligations were imposed, with a median time of 3.95 years (IQR 1.73–5.23) from CMA approval to the latest due date. By 31 March 2025, 53.8% remained under CMA, 38.5% converted to standard marketing authorisation, and 7.7% were withdrawn. Median time to regulatory resolution was 4.46 years. Only 16.7% (3/18) demonstrated substantial clinical benefit according to ESMO–MCBS. Most medicines were subsequently incorporated into ESMO or EHA clinical practice guidelines, although only five (19.2%) received an IA recommendation corresponding to their first CMA-approved indication; two additional medicines received IA recommendations in earlier treatment settings. Public reimbursement was granted for 84.6% (22/26), with a median time of 2.38 years. Conclusion: Oncology medicines granted CMA were frequently supported by limited and immature evidence, while substantial clinical benefit was uncommon and regulatory resolution often required several years. Future optimisation should combine timely access with timely post-authorisation evidence generation, including comparative clinical and real-world evidence.
SN - 1663-9812
ER -